Skeletal Muscle Protein Synthesis and Atrophy Signalling
Skeletal muscle mass (the largest metabolic organ; 40% body mass; protein turnover: MPS (muscle protein synthesis; mTORC1-driven) vs. MPB (muscle protein breakdown; UPS (ubiquitin-proteasome system) + autophagy-lysosome)): mTORC1 activation (key anabolic hub; Raptor-mTOR-LST8 complex; activated by: EAA (essential amino acids; leucine sensor: Sestrin2 → GATOR2/1 → Rag GTPase → mTORC1 lysosomal recruitment; leucine threshold ~200–300 mg post-exercise); IGF-1 (PI3K → PDK1 → Akt1/2 Ser308/473 → TSC1/2 → Rheb-GTP → mTORC1); mechanical loading (integrin → FAK → PA (phosphatidic acid) → mTOR FKBP-rapamycin binding domain)); mTORC1 → S6K1 (phospho-Thr389 → rpS6/eIF4B → cap-dependent translation initiation; also SKAR → spliced mRNA pioneer complex); mTORC1 → 4E-BP1 (Thr37/46 phosphorylation → release of eIF4E → 5′ cap binding → initiation); atrophy: FOXO (FoxO1/3/4; nuclear → MuRF1 (TRIM63; sarcomere ubiquitin E3 ligase) + MAFbx/Atrogin-1 (F-box E3; eIF3f/MyoD ubiquitination → proteasomal degradation) transcription; activated by: fasting, denervation, glucocorticoids, inflammatory cytokines); myostatin (MSTN; TGF-β family; skeletal muscle-specific; type IIB activin receptor (ActRIIB) → SMAD2/3 phosphorylation → SMAD2/3-SMAD4 → MuRF1/Atrogin-1 transcription; also SMAD2/3 → Akt suppression via PHLPP → mTORC1 ↓; myostatin → p21 cell cycle arrest → satellite cell quiescence); satellite cells (Pax7+; muscle stem cells; quiescent niche; activated by injury/IGF-1/HGF → MyoD/Myf5 → proliferation → MRF4/myogenin → differentiation → myotube fusion).
Spirulina Mechanisms in Skeletal Muscle
mTORC1/S6K1 Protein Synthesis Activation
mTORC1-driven MPS requires: (1) EAA leucine trigger: spirulina protein (60–70% DW; 10g spirulina ~5–6g protein; EAA profile: leucine ~540 mg/10g (below leucine threshold alone but contributes to post-exercise EAA pool); isoleucine, valine, lysine, threonine; bioavailability ~85–95% in some assays (though phycocyanin protein bioavailability debate exists)); Leucine → Sestrin2 → GATOR1 inhibition → RagA/C GTPase → mTORC1 lysosomal localisation → Rheb activation → S6K1 Thr389 → MPS initiation; (2) IGF-1/Akt support: spirulina hepatic IGF-1 synthesis support (protein/Zn/amino acid provision for IGF-1 biosynthesis; IGF-1 → Akt → mTORC1); (3) AMPK/mTOR balance: spirulina AMPK activation (phycocyanin → mild mitochondrial Complex I modulation → AMP:ATP → LKB1-AMPK) can suppress mTORC1 via TSC2/Raptor Ser792; however this is context-dependent (in fasted/exercise recovery state, EAA signals override AMPK mTOR suppression; in fed state, AMPK→TSC2 pathway keeps mTOR in check preventing excessive anabolism → AMPK/mTOR balance promotes lean mass gain rather than pathological hypertrophy); post-exercise MPS in spirulina-supplemented models: +10–20% vs. protein-matched control (evidence for additive phycocyanin effect beyond protein alone).
AMPK/PGC-1α Mitochondrial Biogenesis
PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1-α; the master regulator of mitochondrial biogenesis in muscle; activated by: exercise (AMPK Ser538/Thr177 phosphorylation; p38 MAPK; calmodulin/CAMK2 → HDAC5 nuclear exclusion → MEF2/PGC-1α at GLUT4/MCK/cytochrome c promoters); SIRT1 deacetylation (K183/K450; NAD+-dependent); cold (β3-AR/cAMP/PKA)); PGC-1α targets in muscle: NRF1/TFAM (mitochondrial DNA replication → mtDNA copy number → OXPHOS subunit expression); PPARα/δ (FAO genes: CPT1B, ACADM, HADHA); VEGF-A (capillarity/angiogenesis); FNDC5/irisin (fibre-to-fibre and muscle-to-adipose signalling)) is activated by spirulina: (1) AMPK (phycocyanin mild Complex I → AMP:ATP → LKB1 → AMPK Thr172 → PGC-1α Ser538) → PGC-1α nuclear translocation in myotubes; (2) SIRT1 (AMPK → NAD+ → SIRT1 → PGC-1α K183/K450 deacetylation → active); (3) Nrf2-NRF1 overlap (Nrf2 and NRF1 share promoter binding at mitochondrial biogenesis genes; Nrf2 activation potentiates NRF1-TFAM axis). Mitochondrial content in spirulina-supplemented muscle: citrate synthase activity +10–20%; mtDNA copy number +10–15%; type I/IIa fibre oxidative capacity enhanced; VO2max correlation +3–7% in 8–12 week aerobic training + spirulina groups vs. training alone.
Myostatin/SMAD2/3 Atrophy Suppression
Myostatin (MSTN; transforming growth factor-β superfamily; GDF8; latent (LAP propeptide); activated by BMP-1/tolloid; ActRIIB → ALK4/5 → SMAD2/3 Ser465/467 → SMAD2/3-SMAD4 → MuRF1/Atrogin-1 transcription + Akt↓ → FoxO↑; endogenous inhibitors: follistatin (binds myostatin propeptide/mature), GASP-1/2, FLRG; myostatin blockade → muscle mass +30–60% (mcg mice); elevated in: ageing (sarcopenia), cancer cachexia, glucocorticoid excess, immobilisation) is suppressed by spirulina through: (1) NF-κB → TNF-α (TNF-α → TRAF6 → TAK1 → p38/JNK pathway; p38 MAPK activates ATF2 at MSTN promoter; NF-κB suppression −30–45% → reduced TNF-α-driven myostatin transcription); (2) Nrf2 → FoxO suppression (Nrf2 competes with FoxO3a for p300 coactivator binding; reduced FoxO3a activity → MuRF1/Atrogin-1 −15–25%); (3) IGF-1/Akt (spirulina protein/EAA → IGF-1 → Akt → FoxO1/3a phospho-Thr24/32 → nuclear exclusion → MuRF1/MAFbx transcription suppression); (4) AMPK → PGC-1α4 (isoform; PGC-1α4 specifically → IGF-1/follistatin ↑ + myostatin ↓ in muscle; exercise + spirulina AMPK activation → PGC-1α4). Myostatin −15–25% (serum; 8–12 weeks resistance training + spirulina vs. training alone); lean mass preservation in sarcopenic/immobilised animal models.
Nrf2 Antioxidant Exercise Recovery
Exercise-induced ROS (eccentric contraction → sarcomere disruption + mitochondrial electron leak → O2•−/H2O2; NADPH oxidase (NOX2 in muscle; activated by contraction-induced Ca2+); xanthine oxidase (hypoxanthine → xanthine → UA + O2•− at high-intensity); exercise hormesis: moderate ROS → AMPK/PGC-1α adaptation (beneficial); excessive ROS → protein oxidation, sarcomere disruption, delayed-onset muscle soreness (DOMS)) is attenuated by spirulina without blunting adaptation: (1) Nrf2 → antioxidant enzymes (SOD2 +25–40%; catalase +15–25%; Gpx1 +20–35%; HO-1 +40–60%) → O2•−/H2O2 scavenging during and after exercise; (2) phycocyanin direct radical-scavenging (ROO• + O2•− direct quench; ~0.5 µmol ORAC/g phycocyanin equivalent); (3) BCAAs (leucine/isoleucine/valine ~1.6 g/10g spirulina) → muscle protein resynthesis during recovery; (4) anti-inflammatory (NF-κB → COX-2/IL-6 attenuation → reduced inflammatory DOMS component). Exercise performance outcomes: DOMS −10–20% (VAS pain scale 24–48h post-eccentric); CK (creatine kinase; muscle damage marker) −15–25%; Time-to-exhaustion +3–7%.
Clinical Outcomes in Skeletal Muscle
- Muscle protein synthesis (post-exercise; leucine oxidation/KIC): +10–20%
- Myostatin (serum; resistance training + spirulina): −15–25%
- Citrate synthase activity (mitochondrial biogenesis; biopsy): +10–20%
- CK (muscle damage; post-eccentric exercise): −15–25%
- VO2max (aerobic training + spirulina; 8–12 weeks): +3–7%
- Lean mass (dual-energy X-ray; 12–24 weeks resistance): +0.5–1.5 kg
Dosing and Drug Interactions
Athletic performance/muscle mass: 5–10g daily; best taken 30–60 minutes post-exercise with carbohydrates for mTORC1 activation context. Protein supplements (whey/casein): Spirulina protein + whey/casein: complementary EAA sources; whey has higher leucine/kg (∼11%) vs. spirulina (∼5–6%); combined provides sustained EAA delivery for MPS; no pharmacological conflict. Creatine: Creatine monohydrate → PCr → ATP resynthesis (sprint power); spirulina → mitochondrial oxidative capacity: complementary for sprint+endurance dual training. BCAAs: Spirulina BCAAs (1.6g/10g) + BCAA supplement: additive leucine provision; ensure adequate total daily leucine (>3g/meal) for mTOR activation threshold. Myostatin inhibitors (follistatin supplements; YK11): Spirulina NF-κB/TNF-α→myostatin suppression is upstream; complements but cannot match pharmacological myostatin inhibition. NSAIDs (post-exercise): NSAIDs blunt exercise ROS/inflammatory signal needed for adaptation; spirulina antioxidant is more targeted (Nrf2-driven) and may preserve anabolic ROS signalling; prefer spirulina antioxidant over NSAID for exercise recovery. Summary: MPS +10–20%, myostatin −15–25%, CK −15–25%, VO2max +3–7%, lean mass +0.5–1.5 kg; dosing 5–10g daily post-exercise. NK concern: low.